Table 1 Association between RUNX2 expression and clinicopathological variables of the studied CRC patients

From: MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis

Variables Low RUNX2 expression (n = 73) High RUNX2 expression (n = 51) P
  n (%) n (%)  
Age
>65 16 (21.92) 7 (13.73) 0.3481
≤65 57 (78.08) 44 (86.27)  
Gender
Male 41 (56.16) 37 (72.55) 0.0894
Female 32 (43.84) 14 (27.45)  
Tumor site
Rectum 40 (54.79) 33 (64.71) 0.3543
Colon 33 (45.21) 18 (35.29)  
Tumor differentiation
Well 18 (24.66) 21 (41.18) 0.0761
Moderate + poor 55 (75.34) 30 (58.82)  
TNM stage
Stage II 37 (50.68) 10 (19.61) 0.0006
Stage III 36 (49.32) 41 (80.39)  
Lymph vascular invasion
Positive 48 (65.75) 38 (74.51) 0.3282
Negative 25 (34.25) 13 (25.49)  
Perineural invasion
Positive 56 (76.71) 42 (82.35) 0.8301
Negative 17 (23.29) 9 (17.65)  
Liver metastasis
Positive 10 (13.70) 21 (41.18) 0.0007
Negative 63 (86.30) 30 (58.82)  
Lung metastasis
Positive 1 (1.37) 8 (15.69) 0.0035
Negative 72 (98.63) 43 (84.31)  
  1. The bold P values are considered statistically significant